Real-World Glycemic Outcomes of > 400 Adults with Type 2 Diabetes Using the Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based Data Management

The Omnipod 5 AID System is a novel tubeless hybrid closed-loop system approved for use in people with type 1 diabetes ages 2 and up and was recently evaluated in adults with type 2 diabetes (T2D) during an 8-week outpatient feasibility study. The System allows for personalized therapy through customizable glucose targets from 110-150mg/dL in 10mg/dL increments and enables automatic upload of data for all users, facilitating unprecedented access to evaluate real-world outcomes. Continuous glucose monitoring (CGM) and insulin data from Omnipod 5 users with T2D aged ≥18y in the US with ≥90 days of data available in the cloud-based data management system were included. Data from 417 users with sufficient CGM data (≥75% of days with ≥220 readings) and using the lowest target (110mg/dL) for ≥50% of the time, aged 18 to 49y (n=108), 50 to 64y (n=156), and ≥65y (n=153), were available at the time of analysis. Users were aged mean±SD 57.9±12.8y with median 131 days of system use. Outcomes are shown in the Table. Median time in target range (70-180mg/dL) was 68.7%, 71.7%, and 74.0% for each age group, respectively. Time spent in hypoglycemia (<70mg/dL) was low (median 0.3%) in each age group. These data are the first to provide valuable insights to the highly favorable impact of AID on real-world glycemic outcomes among adults with T2D using the Omnipod 5 System. Disclosure A.L.Peters: Advisory Panel; Abbott Diabetes, Medscape, Novo Nordisk, Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S, Research Support; Abbott Diabetes, Dexcom, Inc., Insulet Corporation, Stock/Shareholder; Omada Health, Inc., Livongo. F.J.Pasquel: Consultant; Dexcom, Inc., Medscape, Research Support; Dexcom, Inc., Ideal Medical Technologies. L.M.Huyett: Employee; Insulet Corporation, Stock/Shareholder; Insulet Corporation. K.Snow: Employee; Insulet Corporation. J.J.Mendez: None. I.Hadjiyianni: Employee; Insulet Corporation, Stock/Shareholder; Insulet Corporation, Eli Lilly and Company. T.T.Ly: Employee; Insulet Corporation. Funding Insulet Corporation